Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax - Archive ouverte HAL Access content directly
Journal Articles MSphere Year : 2019

Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

(1, 2, 3, 4) , (1) , (1, 3) , (1, 5)
1
2
3
4
5

Abstract

Inhalational anthrax caused by Bacillus anthracis, a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demonstrates that anthrax antitoxin therapy has any significant benefit. We discuss here the rational basis of anti-PA development regarding the pathogenesis of the disease. We argue that inductive reasoning may induce therapeutic bias. We identified anthrax animal model analysis as another bias. Further studies are needed to assess the benefit of anti-PA antibodies in the treatment of inhalational anthrax, while a clearer consensus should be established around what evidence should be proven in an anthrax model.
Fichier principal
Vignette du fichier
mSphere.00282-19.pdf (789.56 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

pasteur-03293178 , version 1 (20-07-2021)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Jean-Nicolas Tournier, Clémence Rougeaux, Fabrice V. Biot, Pierre L. Goossens. Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax. MSphere, 2019, 4 (3), pp.e00282-19. ⟨10.1128/mSphere.00282-19⟩. ⟨pasteur-03293178⟩

Collections

PASTEUR SSA CNRS
32 View
24 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More